KR0159502B1 - 피라졸로피리딘 화합물과 그것의 제조 방법 - Google Patents

피라졸로피리딘 화합물과 그것의 제조 방법 Download PDF

Info

Publication number
KR0159502B1
KR0159502B1 KR1019900000690A KR900000690A KR0159502B1 KR 0159502 B1 KR0159502 B1 KR 0159502B1 KR 1019900000690 A KR1019900000690 A KR 1019900000690A KR 900000690 A KR900000690 A KR 900000690A KR 0159502 B1 KR0159502 B1 KR 0159502B1
Authority
KR
South Korea
Prior art keywords
alkyl
oxo
carboxy
compound
phenylpyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900000690A
Other languages
English (en)
Korean (ko)
Other versions
KR900011773A (ko
Inventor
유이치 시오카와
아츠시 아카한
히로히토 가타야마
타카후미 미추나가
Original Assignee
후지사와 토모키치로
후지사와 야쿠힝 코교 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 토모키치로, 후지사와 야쿠힝 코교 가부시기가이샤 filed Critical 후지사와 토모키치로
Publication of KR900011773A publication Critical patent/KR900011773A/ko
Application granted granted Critical
Publication of KR0159502B1 publication Critical patent/KR0159502B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019900000690A 1989-01-23 1990-01-22 피라졸로피리딘 화합물과 그것의 제조 방법 Expired - Fee Related KR0159502B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof
GB8901423.7 1989-01-23

Publications (2)

Publication Number Publication Date
KR900011773A KR900011773A (ko) 1990-08-01
KR0159502B1 true KR0159502B1 (ko) 1998-12-01

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900000690A Expired - Fee Related KR0159502B1 (ko) 1989-01-23 1990-01-22 피라졸로피리딘 화합물과 그것의 제조 방법

Country Status (23)

Country Link
US (1) US4985444A (OSRAM)
EP (1) EP0379979B1 (OSRAM)
JP (2) JPH0794454B2 (OSRAM)
KR (1) KR0159502B1 (OSRAM)
CN (1) CN1031570C (OSRAM)
AT (1) ATE150462T1 (OSRAM)
AU (1) AU628913B2 (OSRAM)
CA (1) CA2008263C (OSRAM)
DE (1) DE69030206T2 (OSRAM)
DK (1) DK0379979T3 (OSRAM)
ES (1) ES2098229T3 (OSRAM)
FI (1) FI96205C (OSRAM)
GB (1) GB8901423D0 (OSRAM)
GR (1) GR3023219T3 (OSRAM)
HU (2) HUT53368A (OSRAM)
IE (1) IE900161L (OSRAM)
IL (1) IL93050A (OSRAM)
NO (1) NO176356C (OSRAM)
PH (1) PH30968A (OSRAM)
PT (1) PT92935B (OSRAM)
RU (1) RU2007403C1 (OSRAM)
UA (1) UA43821C2 (OSRAM)
ZA (1) ZA90200B (OSRAM)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5643938A (en) * 1992-06-10 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds for the treatment of anemia
AU7546794A (en) * 1993-09-06 1995-03-27 Kyowa Hakko Kogyo Co. Ltd. Depression remedy
AU694157B2 (en) * 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
EP0900796B1 (en) * 1996-04-25 2004-12-15 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
EP0989129B1 (en) * 1996-10-04 2002-12-11 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
US6303624B1 (en) 1997-03-18 2001-10-16 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
EP1369421B1 (en) 1997-09-05 2004-11-03 Glaxo Group Limited Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives
WO1999062553A1 (en) * 1998-06-01 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
EP1341788B1 (en) 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridines
CN100415744C (zh) * 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
JP2004525150A (ja) * 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
AU2002305143A1 (en) * 2001-04-27 2002-11-11 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
JP2005500315A (ja) * 2001-06-21 2005-01-06 スミスクライン ビーチャム コーポレーション ヘルペスウイルス感染の予防および治療用イミダゾ［１，２−ａ］ピリジン誘導体
ATE364043T1 (de) * 2001-09-07 2007-06-15 Smithkline Beecham Corp Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
JP2005508955A (ja) * 2001-10-05 2005-04-07 スミスクライン ビーチャム コーポレーション ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1453830B1 (en) * 2001-12-11 2007-09-12 SmithKline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
BRPI0911659B8 (pt) 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
US20110039873A1 (en) * 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
MX2012006994A (es) * 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
JP6073464B2 (ja) 2012-04-26 2017-02-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体
BR112014026493A2 (pt) 2012-04-26 2017-06-27 Bristol Myers Squibb Co derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
WO2013163241A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
CA2910123C (en) * 2013-05-28 2021-11-02 Raqualia Pharma Inc. Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro­pyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
CA2951619C (en) * 2014-08-05 2023-01-10 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
US20220152031A1 (en) * 2019-03-20 2022-05-19 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2022071777A1 (ko) * 2020-09-29 2022-04-07 연세대학교 산학협력단 호흡기 질환의 예방 또는 치료용 조성물 및 예방 또는 치료 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
NL8302134A (nl) * 1982-06-16 1984-01-16 May & Baker Ltd Pyrazolopyridine-derivaat, werkwijze voor de bereiding ervan alsmede farmaceutische samenstellingen, die dit derivaat bevatten.
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
JPS63135381A (ja) * 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
DE3710937A1 (de) * 1987-04-01 1988-10-13 Boehringer Mannheim Gmbh Chromogene verbindungen, ihre herstellung und verwendung als enzymsubstrate
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
AU4869690A (en) 1990-07-26
CN1031570C (zh) 1996-04-17
EP0379979B1 (en) 1997-03-19
DE69030206T2 (de) 1997-07-10
NO900306D0 (no) 1990-01-22
ZA90200B (en) 1990-10-31
JPH02243689A (ja) 1990-09-27
ATE150462T1 (de) 1997-04-15
JPH0881465A (ja) 1996-03-26
PT92935B (pt) 1995-12-29
NO176356C (no) 1995-03-22
IL93050A (en) 1995-05-26
IE900161L (en) 1990-07-23
PH30968A (en) 1997-12-23
HUT53368A (en) 1990-10-28
CN1044656A (zh) 1990-08-15
CA2008263C (en) 2000-03-14
FI96205C (fi) 1996-05-27
GR3023219T3 (en) 1997-07-30
CA2008263A1 (en) 1990-07-23
AU628913B2 (en) 1992-09-24
FI96205B (fi) 1996-02-15
EP0379979A1 (en) 1990-08-01
DE69030206D1 (de) 1997-04-24
ES2098229T3 (es) 1997-05-01
HU211684A9 (en) 1995-12-28
IL93050A0 (en) 1990-11-05
DK0379979T3 (OSRAM) 1997-04-07
FI900307A0 (fi) 1990-01-19
UA43821C2 (uk) 2002-01-15
HU900228D0 (en) 1990-03-28
JPH0794454B2 (ja) 1995-10-11
NO176356B (no) 1994-12-12
RU2007403C1 (ru) 1994-02-15
NO900306L (no) 1990-07-24
US4985444A (en) 1991-01-15
GB8901423D0 (en) 1989-03-15
KR900011773A (ko) 1990-08-01
PT92935A (pt) 1990-07-31

Similar Documents

Publication Publication Date Title
KR0159502B1 (ko) 피라졸로피리딘 화합물과 그것의 제조 방법
US5155114A (en) Method of treatment using pyrazolopyridine compound
US6069156A (en) Indole derivatives as cGMP-PDE inhibitors
US6335336B1 (en) 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US7579355B2 (en) Inhibitors of Akt activity
CA2089767C (en) Pyridinyl thiadiazolyl- and oxadiazolyl derivatives
JP2694535B2 (ja) チアジアジノン化合物
EP0370381B1 (en) 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
CA2370500A1 (en) 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
JPS63239284A (ja) ６−ベンゾキサジニル−および６−ベンゾチアジニル−２，３，４，５−テトラヒドロピリダジン−３−オン類
HU190725B (en) Process for preparing dihydro-pyridine derivatives with antischaemic and hypotensive activity
JP2001517666A (ja) チアゾール誘導体
EP2627653A1 (en) 3 -amino- pyrazole derivatives useful against tuberculosis
JPH072854A (ja) イミダゾピリジン
US4738967A (en) Imidazoisoquinoline compounds useful as anti-ulcerative agents
EP2593453B1 (en) Azaindazole compounds
JP3239506B2 (ja) 複素環式誘導体
WO2000034277A1 (en) Sulfonamide compounds and uses thereof as medicines
JP2001524480A (ja) Ｐ２−プリノセプター７−膜貫通（ｔｍ）ｇ−タンパク質共役受容体アンタゴニストである新規な化合物
CN101273039A (zh) 可用作p38激酶抑制剂的杂二环化合物
US5057526A (en) Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo-[3,2-f]benzoxazole-6-ones
JPS6248679A (ja) カルボスチリル誘導体
KR910000165B1 (ko) 1,2-벤즈이소옥사졸-3-일과 1,2-벤즈이소티아졸-3-일 유도체의 제조방법
JP2002509553A (ja) ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物
DE4120109A1 (de) 3-aryl- oder 3-hetaryl-(beta)-carboline, deren herstellung und verwendung in arzneimitteln

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20030807

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040813

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040813